Different Insulins

[Leadinglights]

I see mention of many different insulins that people use which presumably have different profiles of action making them more suitable for different people. I have never heard mention of Suliqua developed by Sanofi for use by Type 2 diabetics specifically. I only ask as my OH was involved in an aspect of the pen system for delivery of the insulin.

 

[Robin]

I’d never heard of it, so I looked it up. It did gain approval in 2019, but I couldn’t find it on our local CCG formulary. It's a mix of long acting insulin Glargine (like Lantus) and a GLP agonist, which I know some people take separately, I think, as Lyxumia, or Ozempic. I sometimes think doctors don’t like prescribing combination drugs, because you can’t alter the dose of one of them without also altering the other.

 

[grovesy]

I’d never heard of it, so I looked it up. It did gain approval in 2019, but I couldn’t find it on our local CCG formulary. It's a mix of long acting insulin Glargine (like Lantus) and a GLP agonist, which I know some people take separately, I think, as Lyxumia, or Ozempic. I sometimes think doctors don’t like prescribing combination drugs, because you can’t alter the dose of one of them without also altering the other.

Not Insulin but I once attended a lecture by a Pharmacist who was of the that view too!

 

[Leadinglights]

Not Insulin but I once attended a lecture by a Pharmacist who was of the that view too!

So the millions of pounds spent on developing it was a bit if a waste then

 

[Inka]

So the millions of pounds spent on developing it was a bit if a waste then

There was something online that said it could work better than the usual mixed insulin for Type 2. I guess the issue is not being able to alter the dose of the GLP bit, and possibly the price?

 

[grovesy]

So the millions of pounds spent on developing it was a bit if a waste then

Who knows for sure?

 

[mikeyB]

It’s so that they could make money on Glargine, which is out of patent. The combination generates a new patent, thus increasing profits. It’s bugger all to do with patient management, for the reasons previously given.